Home/Pipeline/PSG-103

PSG-103

Rare Genetic Movement Disorder

Phase 1/2Active

Key Facts

Indication
Rare Genetic Movement Disorder
Phase
Phase 1/2
Status
Active
Company

About PharmaSGP

PharmaSGP is a clinical-stage biopharmaceutical company headquartered in Germany with a strategic focus on neurological and rare disease therapeutics. The company has built a diversified pipeline of novel drug candidates, primarily in Phase 2 development, targeting conditions such as Parkinson's disease, epilepsy, and rare genetic disorders. With a public listing providing financial stability, PharmaSGP combines scientific innovation with commercial execution to address complex medical challenges in specialized therapeutic areas.

View full company profile